Interferon-alpha 2B kezelés hatása chronicus C hepatitisben.

Translated title of the contribution: Effect of interferon-alpha2b therapy in chronic hepatitis C

J. Fehér, G. Lengyel, L. Dalmi, K. Dávid, J. Gervain, A. Gógl, G. Horváth, J. Lonovics, Z. Löcsei, Z. Ozsvár, A. Pár, F. Schneider, G. Tolvaj, Z. Tulassay, G. Weisz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In chronic hepatitis C the interferon treatment given three times a week in a dosage of 3 million units (MU) normalizes the values of alanin-amino-transferase in a part of cases (25-40%), and produces bettering in the subjective complains of patients. In the short term therapy (3-6 months) the activity of ALT increases again after leaving the therapy, and the disease becomes active. The aim of this multicenter study in Hungary was to give newer data in the case of longterm efficacy with alpha-interferon. Ninety-one patients with chronic hepatitis C were selected into the open prospective clinical study in university and hospital departments. Treatment protocol was the following: Patients with chronic hepatitis C diagnosed by clinical and histological methods were treated with interferon-alpha 2B given 3 times a week in a dosage of 3 MU. Treatment period had lasted for one year and afterwards the patient had been on control for an other half a year. In non responder cases after 3 month treatment with interferon the dose of therapy was increased for 3 x 5 MU. In 37 cases (40.6%) out of 91 patients the authors found longterm sustained remission and in other 22 cases (24.2%) they observed a partial remission (among them 5 cases with late relapse). The rate of longterm sustained remission under 40 years was higher, than above 40. Higher rate was found when the treatment was started with a shorter chronicity of the disease. On te basis of the results the authors conclude: Interferon-alpha 2B is a good therapeutic modality for the treatment of patients with chronic hepatitis C. Efficacy of therapy is higher in younger patients and also in earlier application.

Original languageHungarian
Pages (from-to)1179-1185
Number of pages7
JournalOrvosi Hetilap
Volume137
Issue number22
Publication statusPublished - Jun 2 1996

Fingerprint

Chronic Hepatitis C
Interferons
interferon alfa-2b
Therapeutics
Hungary
Hospital Departments
Clinical Protocols
Transferases
Interferon-alpha
Multicenter Studies
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fehér, J., Lengyel, G., Dalmi, L., Dávid, K., Gervain, J., Gógl, A., ... Weisz, G. (1996). Interferon-alpha 2B kezelés hatása chronicus C hepatitisben. Orvosi Hetilap, 137(22), 1179-1185.

Interferon-alpha 2B kezelés hatása chronicus C hepatitisben. / Fehér, J.; Lengyel, G.; Dalmi, L.; Dávid, K.; Gervain, J.; Gógl, A.; Horváth, G.; Lonovics, J.; Löcsei, Z.; Ozsvár, Z.; Pár, A.; Schneider, F.; Tolvaj, G.; Tulassay, Z.; Weisz, G.

In: Orvosi Hetilap, Vol. 137, No. 22, 02.06.1996, p. 1179-1185.

Research output: Contribution to journalArticle

Fehér, J, Lengyel, G, Dalmi, L, Dávid, K, Gervain, J, Gógl, A, Horváth, G, Lonovics, J, Löcsei, Z, Ozsvár, Z, Pár, A, Schneider, F, Tolvaj, G, Tulassay, Z & Weisz, G 1996, 'Interferon-alpha 2B kezelés hatása chronicus C hepatitisben.', Orvosi Hetilap, vol. 137, no. 22, pp. 1179-1185.
Fehér J, Lengyel G, Dalmi L, Dávid K, Gervain J, Gógl A et al. Interferon-alpha 2B kezelés hatása chronicus C hepatitisben. Orvosi Hetilap. 1996 Jun 2;137(22):1179-1185.
Fehér, J. ; Lengyel, G. ; Dalmi, L. ; Dávid, K. ; Gervain, J. ; Gógl, A. ; Horváth, G. ; Lonovics, J. ; Löcsei, Z. ; Ozsvár, Z. ; Pár, A. ; Schneider, F. ; Tolvaj, G. ; Tulassay, Z. ; Weisz, G. / Interferon-alpha 2B kezelés hatása chronicus C hepatitisben. In: Orvosi Hetilap. 1996 ; Vol. 137, No. 22. pp. 1179-1185.
@article{0fa5ffcfa7874499ab123d07a957cadd,
title = "Interferon-alpha 2B kezel{\'e}s hat{\'a}sa chronicus C hepatitisben.",
abstract = "In chronic hepatitis C the interferon treatment given three times a week in a dosage of 3 million units (MU) normalizes the values of alanin-amino-transferase in a part of cases (25-40{\%}), and produces bettering in the subjective complains of patients. In the short term therapy (3-6 months) the activity of ALT increases again after leaving the therapy, and the disease becomes active. The aim of this multicenter study in Hungary was to give newer data in the case of longterm efficacy with alpha-interferon. Ninety-one patients with chronic hepatitis C were selected into the open prospective clinical study in university and hospital departments. Treatment protocol was the following: Patients with chronic hepatitis C diagnosed by clinical and histological methods were treated with interferon-alpha 2B given 3 times a week in a dosage of 3 MU. Treatment period had lasted for one year and afterwards the patient had been on control for an other half a year. In non responder cases after 3 month treatment with interferon the dose of therapy was increased for 3 x 5 MU. In 37 cases (40.6{\%}) out of 91 patients the authors found longterm sustained remission and in other 22 cases (24.2{\%}) they observed a partial remission (among them 5 cases with late relapse). The rate of longterm sustained remission under 40 years was higher, than above 40. Higher rate was found when the treatment was started with a shorter chronicity of the disease. On te basis of the results the authors conclude: Interferon-alpha 2B is a good therapeutic modality for the treatment of patients with chronic hepatitis C. Efficacy of therapy is higher in younger patients and also in earlier application.",
author = "J. Feh{\'e}r and G. Lengyel and L. Dalmi and K. D{\'a}vid and J. Gervain and A. G{\'o}gl and G. Horv{\'a}th and J. Lonovics and Z. L{\"o}csei and Z. Ozsv{\'a}r and A. P{\'a}r and F. Schneider and G. Tolvaj and Z. Tulassay and G. Weisz",
year = "1996",
month = "6",
day = "2",
language = "Hungarian",
volume = "137",
pages = "1179--1185",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - Interferon-alpha 2B kezelés hatása chronicus C hepatitisben.

AU - Fehér, J.

AU - Lengyel, G.

AU - Dalmi, L.

AU - Dávid, K.

AU - Gervain, J.

AU - Gógl, A.

AU - Horváth, G.

AU - Lonovics, J.

AU - Löcsei, Z.

AU - Ozsvár, Z.

AU - Pár, A.

AU - Schneider, F.

AU - Tolvaj, G.

AU - Tulassay, Z.

AU - Weisz, G.

PY - 1996/6/2

Y1 - 1996/6/2

N2 - In chronic hepatitis C the interferon treatment given three times a week in a dosage of 3 million units (MU) normalizes the values of alanin-amino-transferase in a part of cases (25-40%), and produces bettering in the subjective complains of patients. In the short term therapy (3-6 months) the activity of ALT increases again after leaving the therapy, and the disease becomes active. The aim of this multicenter study in Hungary was to give newer data in the case of longterm efficacy with alpha-interferon. Ninety-one patients with chronic hepatitis C were selected into the open prospective clinical study in university and hospital departments. Treatment protocol was the following: Patients with chronic hepatitis C diagnosed by clinical and histological methods were treated with interferon-alpha 2B given 3 times a week in a dosage of 3 MU. Treatment period had lasted for one year and afterwards the patient had been on control for an other half a year. In non responder cases after 3 month treatment with interferon the dose of therapy was increased for 3 x 5 MU. In 37 cases (40.6%) out of 91 patients the authors found longterm sustained remission and in other 22 cases (24.2%) they observed a partial remission (among them 5 cases with late relapse). The rate of longterm sustained remission under 40 years was higher, than above 40. Higher rate was found when the treatment was started with a shorter chronicity of the disease. On te basis of the results the authors conclude: Interferon-alpha 2B is a good therapeutic modality for the treatment of patients with chronic hepatitis C. Efficacy of therapy is higher in younger patients and also in earlier application.

AB - In chronic hepatitis C the interferon treatment given three times a week in a dosage of 3 million units (MU) normalizes the values of alanin-amino-transferase in a part of cases (25-40%), and produces bettering in the subjective complains of patients. In the short term therapy (3-6 months) the activity of ALT increases again after leaving the therapy, and the disease becomes active. The aim of this multicenter study in Hungary was to give newer data in the case of longterm efficacy with alpha-interferon. Ninety-one patients with chronic hepatitis C were selected into the open prospective clinical study in university and hospital departments. Treatment protocol was the following: Patients with chronic hepatitis C diagnosed by clinical and histological methods were treated with interferon-alpha 2B given 3 times a week in a dosage of 3 MU. Treatment period had lasted for one year and afterwards the patient had been on control for an other half a year. In non responder cases after 3 month treatment with interferon the dose of therapy was increased for 3 x 5 MU. In 37 cases (40.6%) out of 91 patients the authors found longterm sustained remission and in other 22 cases (24.2%) they observed a partial remission (among them 5 cases with late relapse). The rate of longterm sustained remission under 40 years was higher, than above 40. Higher rate was found when the treatment was started with a shorter chronicity of the disease. On te basis of the results the authors conclude: Interferon-alpha 2B is a good therapeutic modality for the treatment of patients with chronic hepatitis C. Efficacy of therapy is higher in younger patients and also in earlier application.

UR - http://www.scopus.com/inward/record.url?scp=0030563975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030563975&partnerID=8YFLogxK

M3 - Article

C2 - 8757098

AN - SCOPUS:0030563975

VL - 137

SP - 1179

EP - 1185

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -